CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
RTOG-P-0011 | RTOG | Phase III Randomized Study of Adjuvant Therapy For High Risk PT2-3N0 Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed |
CALGB-90202 | CALGB | A Randomized Double-Blind; Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone | Adult CIRB - Late Phase Emphasis | Completed |
NRG-HN004 | NRG | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin | Adult CIRB - Late Phase Emphasis | Available to Open |
10231 | NCORP-National Institutes of Health | NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study | Adult CIRB - Late Phase Emphasis | Available to Open |
S1900K | RTOG | A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) | Adult CIRB - Late Phase Emphasis | Available to Open |
S1827 | SWOG | MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) | Adult CIRB - Late Phase Emphasis | Available to Open |
GOG-0219 | GOG | A Phase III; Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2; IIA; IIB; IIIB; and IVA Cervical Carcinoma Limited to the Pelvis | Adult CIRB - Late Phase Emphasis | Completed |
E3999 | ECOG | A Randomized; Placebo-controlled; Double Blind; Trial of the Administration of the MDR Modulator; Zosuquidar Trihydrochloride (LY335979); During Conventional Induction and Post-Remission Therapy in Patients Greater than 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia; Refractory Anemia with Excess Blasts in Transformation or High-Risk Refractory Anemia with Excess Blasts | Adult CIRB - Late Phase Emphasis | Completed |
NRG-BN009 | NRG | Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse after Upfront SRS with Brain Metastasis Velocity ≥4 Brain Metastases/Year | Adult CIRB - Late Phase Emphasis | Available to Open |
S0421 | SWOG | Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed |